The Company reported cash and short-term investments of $52.4 million at June 30, 2023, excluding restricted cash. In addition, CorMedix received approximately $43.2 million in net proceeds from its equity financing that closed in July of 2023. The Company believes that it has sufficient resources to fund operations for at least twelve months from the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRMD:
- CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
- Cormedix Inc. (CRMD) Q2 Earnings Cheat Sheet
- 2 ‘Strong Buy’ Penny Stocks With Massive 300% Upside Potential — Or More
- CorMedix Tanks on $40M Securities Offering
- CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants